Fabien Dutheil*, Youssef Slama
Androgen deprivation is a key treatment in the management of patient with locally advanced and metastatic prostate cancer. A better comprehension of the castration resistance's mechanisms allowed the development of second-generation hormonal therapies that are generally better tolerated than chemotherapy and can improve the survival and quality of life of patients with prostate cancer.